These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 24441503

  • 1. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
    Christoph DC, Eberhardt WE.
    Curr Opin Oncol; 2014 Mar; 26(2):171-81. PubMed ID: 24441503
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [Abstract] [Full Text] [Related]

  • 3. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T, Itano H, Fukita S, Saitoh M, Takeda S.
    Intern Med; 2014 Mar; 53(20):2347-51. PubMed ID: 25318801
    [Abstract] [Full Text] [Related]

  • 4. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.
    Clin Cancer Res; 2014 Dec 01; 20(23):5927-36. PubMed ID: 25231400
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I.
    Clin Lung Cancer; 2014 May 01; 15(3):197-201. PubMed ID: 24492162
    [Abstract] [Full Text] [Related]

  • 6. [Malignant pleural mesothelioma: 2013 state of the art].
    Campbell K, Brosseau S, Reviron-Rabec L, Bergot E, Lechapt E, Levallet G, Zalcman G.
    Bull Cancer; 2013 Dec 01; 100(12):1283-93. PubMed ID: 24225007
    [Abstract] [Full Text] [Related]

  • 7. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 8. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G.
    Future Oncol; 2017 Dec 01; 13(28):2537-2546. PubMed ID: 29086616
    [Abstract] [Full Text] [Related]

  • 9. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
    Maehara S, Usuda J, Ishizumi T, Ichinose S, Ohtani K, Inoue T, Imai K, Furumoto H, Kudo Y, Kajiwara N, Ohira T, Ikeda N.
    Int J Oncol; 2015 Feb 01; 46(2):741-9. PubMed ID: 25385189
    [Abstract] [Full Text] [Related]

  • 10. Standard therapy for the treatment of malignant pleural mesothelioma.
    Vogelzang NJ.
    Lung Cancer; 2005 Oct 01; 50 Suppl 1():S23-4. PubMed ID: 16291429
    [Abstract] [Full Text] [Related]

  • 11. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X.
    Rev Mal Respir; 2018 Apr 01; 35(4):465-476. PubMed ID: 29415822
    [Abstract] [Full Text] [Related]

  • 12. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
    Kondola S, Manners D, Nowak AK.
    Ther Adv Respir Dis; 2016 Jun 01; 10(3):275-88. PubMed ID: 26873306
    [Abstract] [Full Text] [Related]

  • 13. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y.
    Int J Clin Oncol; 2014 Aug 01; 19(4):601-6. PubMed ID: 24158772
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT).
    Lancet; 2016 Apr 02; 387(10026):1405-1414. PubMed ID: 26719230
    [Abstract] [Full Text] [Related]

  • 15. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
    Hayashi H, Okamoto I, Ichikawa Y, Miyazaki M, Yoshioka H, Kunimasa K, Nakagawa K.
    Int J Clin Oncol; 2010 Oct 02; 15(5):497-9. PubMed ID: 20224880
    [Abstract] [Full Text] [Related]

  • 16. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.
    Respir Investig; 2014 Mar 02; 52(2):101-6. PubMed ID: 24636265
    [Abstract] [Full Text] [Related]

  • 17. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M, Gatzemeier U.
    Expert Rev Anticancer Ther; 2005 Apr 02; 5(2):231-7. PubMed ID: 15877521
    [Abstract] [Full Text] [Related]

  • 18. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
    Green J, Dundar Y, Dodd S, Dickson R, Walley T.
    Cochrane Database Syst Rev; 2007 Jan 24; 2007(1):CD005574. PubMed ID: 17253564
    [Abstract] [Full Text] [Related]

  • 19. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
    Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL.
    Lung Cancer; 2012 Sep 24; 77(3):567-71. PubMed ID: 22770372
    [Abstract] [Full Text] [Related]

  • 20. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar 24; 36(3):162-8. PubMed ID: 23856136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.